NCT01001338View on ClinicalTrials.gov

Allopurinol Combination Study

PHASE2CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

August 31, 2016

Conditions
Gout
Interventions
DRUG

RDEA594

Uricosuric agent for the treatment of gout.

DRUG

Placebo

Matching Placebo

DRUG

Allopurinol

Allopurinol

Trial Locations (44)

20902

Wheaton

21081

Vinnytsia

23320

Chesapeake

27710

Durham

28075

Harrisburg

29732

Rock Hill

32720

DeLand

33334

Fort Lauderdale

33432

Boca Raton

33458

Jupiter

38138

Germantown

38305

Jackson

40504

Lexington

44122

Cleveland

44143

Mayfield Village

45242

Cincinnati

48903

Bilbao

61176

Kharkiv

75231

Dallas

78221

San Antonio

83045

Donetsk

83642

Meridan

84088

West Jordan

85050

Phoenix

89183

Las Vegas

89502

Reno

90017

Los Angeles

92037

La Jolla

94305

Stanford

V3K 3P4

Coquitlam

V1Y8E7

Kelowna

A1A 3R5

St. John's

L4J 6W6

Thornhill

M9W 4L6

Toronto

J7J 2K8

Mirabel

85-168

Bydgoszcz

82-300

Elblag

20-607

Lublin

60-773

Poznan

26-610

Radom

87-100

Torun

01610

Kyiv

02125

Kyiv

FY4 3AD

Blackpool

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT01001338 - Allopurinol Combination Study | Biotech Hunter | Biotech Hunter